

Alshad S Lalani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9523164/publications.pdf>

Version: 2024-02-01

27
papers

1,701
citations

471509

17
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

2774
citing authors

#	ARTICLE	IF	CITATIONS
1	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	27.8	572
2	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	7.0	170
3	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
4	Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous <i>HER2</i> +ve breast cancer metastasis. <i>Breast Cancer Research</i> , 2019, 21, 94.	5.0	87
5	An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with <i>HER2</i> Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 575-585.	9.4	85
6	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
7	Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 277-289.	7.0	74
8	Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of <i>HER2</i> -Positive and <i>HER2</i> -Mutated Breast Cancer. <i>Cancers</i> , 2019, 11, 737.	3.7	65
9	HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 90262-90277.	1.8	57
10	Neratinib is effective in breast tumors bearing both amplification and mutation of <i>ERBB2</i> (<i>HER2</i>). <i>Science Signaling</i> , 2018, 11, .	3.6	53
11	Co-occurring gain-of-function mutations in <i>HER2</i> and <i>HER3</i> modulate <i>HER2/HER3</i> activation, oncogenesis, and <i>HER2</i> inhibitor sensitivity. <i>Cancer Cell</i> , 2021, 39, 1099-1114.e8.	16.8	45
12	Comparative analysis of drug response and gene profiling of <i>HER2</i> -targeted tyrosine kinase inhibitors. <i>British Journal of Cancer</i> , 2021, 124, 1249-1259.	6.4	34
13	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in <i>HER2</i> -Mutant Cancers. <i>Cancer Cell</i> , 2020, 37, 183-199.e5.	16.8	33
14	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of <i>HER2</i> -positive Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1681-1694.	7.0	33
15	Neratinib augments the lethality of [regorafenib+sildenafil]. <i>Journal of Cellular Physiology</i> , 2019, 234, 4874-4887.	4.1	32
16	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in <i>HER2</i> -Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	7.0	31
17	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/ <i>HER2</i> Crosstalk and Maintains Complete Responses of ER+/ <i>HER2</i> + Breast Cancers: Implications to the ExteNET Trial. <i>Clinical Cancer Research</i> , 2019, 25, 771-783.	7.0	29
18	GCN2 kinase activation by ATP-competitive kinase inhibitors. <i>Nature Chemical Biology</i> , 2022, 18, 207-215.	8.0	19

#	ARTICLE	IF	CITATIONS
19	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	5.0	17
20	PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. <i>Biomedicines</i> , 2021, 9, 740.	3.2	10
21	Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition. <i>Cancer Biology and Therapy</i> , 2019, 20, 157-168.	3.4	9
22	The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00521.	2.4	5
23	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 55-63.	2.5	3
24	Abstract 4038: Exploring optimal targeted combination therapies with neratinib for HER2+breast cancer. , 2017, , .		3
25	Natural History and Characteristics of <i>ERBB2</i> -mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE. <i>Clinical Cancer Research</i> , 2022, 28, 2118-2130.	7.0	3
26	Abstract 1453: Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. , 2021, , .		0
27	Abstract 1181: Neratinib induces synthetic lethality with PARP inhibitors in triple negative breast cancer cells <i>in vitro</i> and <i>in vivo</i> . , 2021, , .		0